Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/Gastroenterology.1.001
Hepatitis Treatment in the Last 20 Years: A Short Review
- 1Academic Teaching Hospital Bethesda Duisburg, Department of Gastroenterology, Heerstr. 219, 47053 Duisburg, Germany
Abdurrahman Sagir, email@example.com
Received Date: March 23, 2020
Accepted Date: March 30, 2020
Sagir A. Hepatitis Treatment in the Last 20 Years: A Short Review. Arch Gastroenterol Res. 2020; 1(1): 1-3.
Copyright: © 2020 Sagir A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
As the new editor-in-chief of Archives of Gastroenterology Research (AGR) I cordially welcome all current readers of AGR and future contributors to AGR. Together with my editorial team of AGR we encourage scientists and clinicians involved in the care of patients with gastrointestinal diseases to submit their interesting reports to AGR with the aim to be published following fair evaluation by external peer reviewers
Chronic hepatitis C infection is a global public health problem affecting more than 71 million people. Treatment of hepatitis C virus (HCV) has rapidly advanced with the introduction of oral direct-acting antivirals (DAAs).
The development of direct-acting antiviral agents for the treatment of Hepatitis C (HCV) has changed the practice of treating patients with HCV. In particular, organ transplant recipients who have not previously been exposed to HCV are now able to consider receiving an organ from a donor who is infected with HCV, and anticipate effective antiviral therapy after transplantation.